ABIONYX Pharma successfully completes its capital increase

ABIONYX Pharma announces a capital increase of €18.7 million through the issuance of 7,056,416 new shares, fully subscribed with maintenance of shareholders' preferential subscription rights. In parallel, the company has drawn down a first tranche of €10 million in bond financing, provided by the Danish fund Fenja Capital. These financial operations are intended, in particular, to finance a Phase 2b clinical trial for sepsis and to advance the marketing authorization application for the treatment of LCAT deficiency.

Following these transactions, ABIONYX's share capital will consist of 42,568,071 shares. Settlement and delivery of the new shares is scheduled for June 22, 2026. Fenja Capital may subscribe to additional warrants, providing further funds under pre-established conditions.

This funding extends ABIONYX's cash horizon to the fourth quarter of 2028, strengthening its position to pursue its clinical and strategic developments.